August 1, 2014

Association of Ringside Physicians Takes a Strong Stand on TUEs for TRT

Should testosterone supplementation for a diagnosis of primary or secondary hypogonadism be allowed in boxing/MMA?


August 1, 2014

ARP Board Member Dr. Nick Rizzo Discusses TRT/TUEs/PEDs with NHB’s Eddie Goldman

Article by: Eddie Goldman 

Original article @ http://nhbnews.podomatic.com/entry/2014-02-15T08_03_00-08_00

On this edition of No Holds Barred, host Eddie Goldman spoke with Dr. Nicholas Rizzo.

Dr. Rizzo is a board-certified internist, a former wrestler and wrestling coach, a ringside physician for professional boxing and MMA events, and a member of the Board of Directors of the Association of Ringside Physicians.

On January 27, 2014, the Association of Ringside Physicians issued a statement which said “the Association of Ringside Physicians supports the general elimination of therapeutic use exemptions (TUE) for testosterone replacement therapy.”

We spoke with Dr, Rizzo by phone Wednesday about this issue.

Here is the body of that statement:

“The ARP Releases a Consensus Statement on Therapeutic Use Exemptions for Testosterone Replacement Therapy in Professional Boxing and Mixed Martial Arts.

“The Association of Ringside Physicians (ARP), an international, non-profit organization dedicated to the health and safety of the boxer and mixed martial arts athlete, has released a consensus statement on therapeutic use exemptions for testosterone replacement therapy in professional combat sport athletes, as follows:

“‘The incidence of hypogonadism requiring the use of testosterone replacement therapy (TRT) in professional athletes is extraordinarily rare. Accordingly, the use of an anabolic steroid such as testosterone in a professional boxer or mixed martial artist is rarely justified. Steroid use of any type, including unmerited testosterone, significantly increases the safety and health risk to combat sports athletes and their opponents. TRT in a combat sports athlete may also create an unfair advantage contradictory to the integrity of sport. Consequently, the Association of Ringside Physicians supports the general elimination of therapeutic use exemptions (TUE) for testosterone replacement therapy.’

“For more about the ARP, visit their website at www.associationofringsidephysicians.org.”

Besides discussing the many reasons for this position, Dr. Rizzo noted in this interview: “There’s some report that just came out that states that long-term testosterone replacement therapy may be associated with heart disease. Now, it’s a preliminary report, the jury’s still out, the concrete data’s not in. But anytime you’re introducing something artificial, you need to weigh the risks and benefits. And one of the caveats of medicine is ‘Primum non nocere,’ which is Latin for ‘First, do no harm.'”


While he is not entirely opposed to granting therapeutic use exemptions for testosterone replacement therapy, he believes that the actual number of professional athletes who require this and who would not be given an unfair advantage by this is quite small. “You can count them on one hand on a national level,” he said.

The No Holds Barred theme song is called “The Heist”, which is also available on iTunes by composer Ian Snow.

No Holds Barred is free to listen to and is sponsored by:

ONE Fighting Championship. ONE FC is Asia’s largest and most prestigious mixed martial arts event. ONE FC features the best Asian fighters and has initiated the ONE Asia Partnership Network, which includes most of the major MMA promotions and MMA gyms in Asia. For more information, go to their web site, at ONEFC.com.

American Top Team. Whether you’re a beginner or a champion, train with the champions in Brazilian Jiu-Jitsu, boxing, wrestling, grappling, and mixed martial arts at American Top Team. Check out their web site at http://americantopteam.com/.

Thanks, Eddie Goldman


August 1, 2014

USA Today on TRT doubling the risk of heart attacks

Original Article at: http://www.usatoday.com/story/news/nation/2014/01/29/testosterone-heart-risks/4967795/


Taking testosterone therapy doubled the risk of heart attack among men over age 65 and nearly tripled the risk in younger men with a history of heart disease, a new study shows.

The report, which involved 56,000 men, is the latest in a series of studies raising concerns about the heart attack risk from testosterone therapy, whose popularity has ballooned in recent years. The study was published Wednesday in PLOS One.

Francisco Lopez-Jimenez, a cardiologist at the Mayo Clinic in Minnesota not involved in the new study, describes the heart risks posed by testosterone therapy as substantial.

“That’s equivalent to smoking one or two packs of cigarettes a day, or having sky-high cholesterol,” Lopez-Jimenez says.

Authors of the study, led by researchers at the University of California-Los Angeles and others, say doctors should discuss these risks with patients. Testosterone is often called the “male hormone” because it causes development of male sex organs, facial hair and other masculine features.

Doctors recommend testosterone therapy to treat hypogonadism, which causes abnormally low testosterone levels. Studies show that testosterone can improve sexual function, bone density, lean muscle mass and strength while lowering cholesterol and insulin resistance, a condition that increases the risk of diabetes.

Drug companies also have marketed testosterone directly to consumers, however, urging men to consider hormones to treat the symptoms of “low T,” which are said to include energy loss, mood changes and reduced sex drive.

Those ads appear to have been hugely successful.

Doctors wrote more than 5.3 million prescriptions for testosterone therapy in 2011, five times as many as in 2000, according to a November report in the Journal of the American Medical Association. The number of men taking testosterone tripled from 2001 to 2011, with the drugs now used by nearly 4% of men in their 60s, according to a separate study last year in JAMA Internal Medicine.

Yet only about half of men taking testosterone therapy had been diagnosed with hypogonadism, and 25% hadn’t even had their testosterone levels tested, according to the JAMA Internal Medicine study. The rest of patients had been diagnosed with other problems such as fatigue or sexual dysfunction.

A spokesman for AbbVie, which makes AndroGel, one of the most popular testosterone therapies, notes that studies also have found health benefits from the medications. A 2012 study linked testosterone with a lower risk of death. A 2013 study in the Journal of Clinical Practice found that men taking the therapy long-term had healthier cholesterol levels, blood sugar levels and blood pressure.

“We encourage discussion between physicians and patients that leads to proper diagnosis based on symptoms, lab tests and a patient’s other health needs,” says David Freundel, a spokesman for AbbVie.

Abraham Morgentaler, an associate clinical professor of urology at Harvard Medical School, says it’s possible that the men’s heart attacks in this study were caused by their underlying medical problems, not by testosterone. He notes that most heart attacks occurred in the first 90 days after a prescription was written. It’s unlikely that heart attacks could develop in such a short period of time, he says.

Cardiologist Steven Nissen says the Food and Drug Administration should require companies that sell testosterone therapy to conduct rigorous clinical trials examining the medication’s heart risks.

Nissen, chair of cardiovascular medicine at the Cleveland Clinic, notes that hormones have powerful and sometimes surprising effects throughout the body, not just on sexual organs. He cited hormone replacement therapy, which was once touted as a way to prevent heart disease in women but was later found to cause heart attacks, strokes and breast cancer. Prescribing testosterone therapy to thousands of men who may not really need it, he says, is “a “gigantic experiment, and I’m extremely concerned.”